Trials / Completed
CompletedNCT02142634
Budesonide for Induction of Remission in Incomplete Microscopic Colitis
Randomised, Double-blind, Placebo-controlled, Multi-centre Trial on the Efficacy and Safety of Budesonide for Induction of Remission in Incomplete Microscopic Colitis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 44 (actual)
- Sponsor
- Dr. Falk Pharma GmbH · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to demonstrate the efficacy of budesonide for the treatment of active incomplete microscopic colitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Budesonide granules 9 mg | per day |
| DRUG | Placebo granules | per day |
Timeline
- Start date
- 2014-05-01
- Primary completion
- 2020-02-01
- Completion
- 2020-02-01
- First posted
- 2014-05-20
- Last updated
- 2020-07-22
Locations
2 sites across 2 countries: Germany, Sweden
Source: ClinicalTrials.gov record NCT02142634. Inclusion in this directory is not an endorsement.